U.S. Stem Cell
U.S. Stem Cell Inc. is a pre-revenue, publicly-traded biotechnology company developing MyoCell, an autologous cell therapy for cardiac scar tissue, targeting patients with heart damage. The company remains in clinical-stage development with no commercial revenue.
- Company typePublic
- Founded1999
- HeadquartersSunrise, United States
- Headcount11–50
- GTM typeB2C
- OfferingServices
What U.S. Stem Cell does
U.S. Stem Cell Inc. (OTC: USRM) is a publicly-traded biotechnology company headquartered in Sunrise, Florida, founded in 1999, that develops autologous cellular therapies for degenerative cardiovascular conditions. Its sole disclosed product, MyoCell, is an autologous cell therapy designed to treat scar tissue in patients' hearts for heart damage repair; the asset is described as being in clinical-trial stage, with no FDA approval, commercialization, or distribution model evidenced in the source data. The company is in pre-revenue development: there is no disclosed pricing, no paying customers, no named partners, and no GTM motion, and its market capitalization has collapsed to roughly $64,150 with the stock declining 99% and trading at virtually zero value by early 2026. Cumulative disclosed equity funding totals less than $900,000 across four rounds between 2010 and 2021, indicating extremely limited capital deployment. Leadership comprises Mike Tomas (President and CEO) and Kristin Comella (Chief Scientific Officer), with 11–50 employees per firmographic data. A material governance/operational red flag is that the corporate website (us-stemcell.com) appears to have been compromised and redirected to an unrelated Vietnamese sports-streaming site, and the financials feed contains implausibly large revenue figures (tens to hundreds of millions of dollars) that are inconsistent with a $64K-market-cap, pre-clinical OTC entity and likely represent data contamination.
U.S. Stem Cell firmographics
Firmographics- Name
- U.S. Stem Cell
- Legal name
- U.S. Stem Cell Inc.
- Website
- https://us-stemcell.com
- Company type
- Public
- Founded year
- 1999
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- U.S. Stem Cell Inc. is a pre-revenue, publicly-traded biotechnology company developing MyoCell, an autologous cell therapy for cardiac scar tissue, targeting patients with heart damage. The company remains in clinical-stage development with no commercial revenue.
- Ownership category
- akta.pro rank
U.S. Stem Cell industry classification
Industry- Product category
- Cell Therapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cell Therapy Developers (Autologous) (HLAAABAA)
- akta.pro secondary industries
- Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis) (HLAAAGAJ), Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables) (HLAAABAH)
Keywords
Where U.S. Stem Cell is headquartered
LocationHeadquarters
- HQ city
- Sunrise
- HQ country
- United States
- HQ region
- North America
Markets served
U.S. Stem Cell business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations
U.S. Stem Cell product offering
Product offeringCore offering
U.S. Stem Cell develops autologous cell therapies for treating heart damage and cardiac scar tissue. The company's primary product is MyoCell, an autologous cell therapy designed to repair scar tissue in patients' hearts. The company is focused on the discovery, development, and regulatory approval of cell-based therapies targeting cardiovascular conditions, currently in clinical trial stage.
Product overview
U.S. Stem Cell is a biotechnology company developing autologous cell therapies for heart damage. The company's primary product is MyoCell, an autologous cell therapy designed to treat scar tissue in patients' hearts. The company is focused on the discovery, development, and regulatory approval of cell-based therapies targeting cardiovascular conditions.
Differentiator
Problem solved
Functional benefit
Products and services
- MyoCell Autologous cell therapy designed to treat scar tissue in patients' hearts, developed for heart damage repair using the patient's own cells. Currently in clinical trial stage targeting patients with heart damage and cardiac scar tissue conditions.
Companies that use U.S. Stem Cell
Customer profileSegments1 record
Ideal customer profiles1 record
U.S. Stem Cell technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
U.S. Stem Cell partnerships and signals
Strategic signalScale indicators5 records
Recent moves5 records
U.S. Stem Cell competitors and assessment
Company assessmentBroad incumbents
- Vericel Corporation: Commercial-stage cell therapy company with approved autologous cell therapy products (MACI, Epicel) — established player in autologous cell therapy commercialization.
- Cellectis: Cell therapy company with focus on gene-edited cell therapies — operates in the broader cell therapy space, offering adjacent enabling technologies.
Direct peers
- BioCardia: CardiAMP cell therapy system for heart failure — develops autologous bone marrow cell therapies for cardiac regeneration, directly competing with MyoCell in the same indication space.
- Mesoblast: Develops cellular therapies for cardiovascular diseases including heart failure, with a lead product (Revascor) targeting cardiac regeneration — directly comparable to U.S. Stem Cell's MyoCell program.
- Capricor Therapeutics: Clinical-stage biotech developing cell therapy (dermatocycler-derived cells, CAP-1002) for Duchenne muscular dystrophy and cardiac indications — directly comparable in cardiac cell therapy development.
- Pluristem Therapeutics: Develops placental-derived allogeneic cell therapy products for cardiovascular and other indications — directly comparable in cardiac regenerative medicine.
- BrainStorm Cell Therapeutics: Cell therapy company developing autologous cellular treatments (NurOwn), with similar small-cap profile and clinical-stage development focus.
- Athersys: Clinical-stage regenerative medicine company developing cell therapies (MultiStem) for cardiovascular and inflammatory conditions — comparable in clinical-stage cell therapy positioning.
- Cytori Therapeutics: Develops cell therapy technologies for cardiovascular and other regenerative medicine applications — historical peer in cardiac cell therapy space.
Emerging players
- Tengion: Regenerative medicine company focused on autologous cell-based therapies for organ and tissue regeneration — similar small-cap regenerative medicine profile.
Market position
Strengths3 records
Weaknesses4 records
Competitive moat1 record
Key risks6 records
Key highlights4 records
Customer concentration
U.S. Stem Cell social profiles
Digital presenceU.S. Stem Cell financial estimates
Financial estimateRevenue estimate
Valuation estimate
U.S. Stem Cell leadership team
Management profileNumber of profiles
Profiles2 records
U.S. Stem Cell funding detail
Funding detailFunding overview
Funding rounds4 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
U.S. Stem Cell M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about U.S. Stem Cell
What does U.S. Stem Cell do?
U.S. Stem Cell develops autologous cell therapies for treating heart damage and cardiac scar tissue. The company's primary product is MyoCell, an autologous cell therapy designed to repair scar tissue in patients' hearts. The company is focused on the discovery, development, and regulatory approval of cell-based therapies targeting cardiovascular conditions, currently in clinical trial stage.
Is U.S. Stem Cell a public or private company?
U.S. Stem Cell is a public company. It is classified as public and is currently operating.
When was U.S. Stem Cell founded?
U.S. Stem Cell was founded in 1999. It employs 11 to 50 people.
Where is U.S. Stem Cell based?
U.S. Stem Cell is headquartered in Sunrise, United States, in the North America region.
Who are U.S. Stem Cell's main competitors?
Broad incumbents on record are Vericel Corporation and Cellectis. Direct peers are BioCardia, Mesoblast, Capricor Therapeutics, Pluristem Therapeutics, BrainStorm Cell Therapeutics, Athersys and Cytori Therapeutics. Tengion is listed as an emerging player.
Does U.S. Stem Cell have an API?
No public API is recorded for U.S. Stem Cell.
What industry is U.S. Stem Cell in?
U.S. Stem Cell's product category is Cell Therapy. Its primary akta.pro industry code is HLAAABAA, Cell Therapy Developers (Autologous), with a secondary code of HLAAAGAJ, Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis). Its NAICS code is 325414 and its SIC code is 2836.